Innate Pharma revenue was €70.45 m in FY, 2020
Innate Pharma revenue breakdown by business segment: 15.0% from Government financing for research expenditures and 85.0% from Revenue from collaboration and licensing agreements
|FY, 2017||FY, 2018|
|Government financing for research expenditures||€11.4 m||€14.06 m|
|Revenue from collaboration and licensing agreements||€32.63 m||€79.89 m|
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.